Anti-angiogenesis strategies in cancer therapeutics / edited by Shaker A. Mousa, Paul J. Davis.

Format:

Book

Contributor:

Mousa, Shaker A.

Davis, Paul J.

ScienceDirect (Online service).

Language:

English

Subjects (All):

Cancer--Chemotherapy.

Cancer.

Physical Description:

1 online resource

Place of Publication:

London : Academic Press is an imprint of Elsevier, [2017]

System Details:

text file

Summary:

Anti-Angiogenesis Strategies in Cancer Therapies provides a detailed overview of the current status and future directions of research in the discovery and development of novel anti-angiogenesis strategies in oncology. Angiogenesis is necessary in the growth and spread of cancer and as a result, targeting the angiogenesis process has become important to developing new cancer therapies for many types of cancer alone and in combination with other anti-cancer agents. This book highlights the different mechanisms involved in the modulation of angiogenesis, including inflammation, thrombosis and microRNA, and shows how nanotechnology can further enhance the potential of existing and new anti-angiogenesis approaches. Written for industry scientists and researchers as well as oncologists, hematologists, and professors and students in the field, this comprehensive book covers all aspects of anti-angiogenesis strategies and the differences among these strategies to outline the best way forward. Key Features, Addresses important preclinical models and clinical trials in the discovery and development of novel anti-angiogenesis agents, and reviews FDA-approved anti-angiogenesis agents, Illustrates the applications of nanotechnology for improving the utility of anti-angiogenesis agents, Considers the current state and future of anti-angiogenesis agent research Book jacket.

Contents:

1 Angiogenesis and Anti-Angiogenesis Strategies in Cancer / Shaker A. Mousa Mousa, Shaker A., Paul J. Davis Davis, Paul J. 1

Process of Angiogenesis 2

Angiogenesis in Cancer 3

Strategies 5

Current Examples of Cancer Treatment Agents that Block Angiogenesis 6

Side Effects of Angiogenesis Inhibitors 7

Angiogenesis and Angiogenesis Inhibitors- Potential Anticancer Therapeutic Efficacy 7

Targeting of VEGF 7

Additional Anti-Angiogenesis Strategies in Cancers 8

Kininostatin 8

Alpha 3 Chain of Type IV Collagen 9

Matrix Metalloproteinases 9

2-Methoxyestradiol 9

Small Molecule Integrin Antagonists 10

Nutraceutical-Derived Polyphenols 10

Anti-Angiogenesis Therapy in Hematologic Cancer: Multiple Myeloma 10

Anti-Coagulants and Angiogenesis 11

Possible Mechanisms of Acquired Resistance to Anti-Angiogenic Drugs 12

Standard Chemotherapy Versus Angiogenesis Inhibitors 13

Anti-Angiogenesis Agents and Thrombosis 13

Diagnostic Imaging of Angiogenesis 13

microRNA and Angiogenesis Modulation 14

References 14

2 Models for Assessing Anti-Angiogenesis Agents: Appraisal of Current Techniques / Shaker A. Mousa Mousa, Shaker A., Murat Yalcin Yalcin, Murat, Paul J. Davis Davis, Paul J. 21

In Vivo Assays 23

Chick Chorioallantoic Membrane 23

Zebrafish 26

Subcutaneous and Orthotopic Xenografts 27

Matrigel Plug Assay 28

In Vitro Assays 30

Aortic Ring Assay 30

Sprouting Assay 30

Tube Formation Assay 31

Three-Dimensional Matrix Array Ultrasound Molecular Imaging 32

Coculture of Human Cancer Cells with Human Microvascular Endothelial Cells 32

Discussion 34

Conclusions 35

References 35

3 Anti-Angiogenesis in Multiple Myeloma / Domenico Ribatti Ribatti, Domenico, Angelo Vacca Vacca, Angelo 39

Angiogenesis in Multiple Myeloma 39

Thalidomide and its Analogs 40

Bortezomib 41

Tyrosine Kinase Inhibitors (TKIs) 44

Zoledronic Acid 44

Conclusions 45

Acknowledgments 46

References 46

4 Interface between Thrombosis, Inflammation, and Angiogenesis In Cancer Progression / Shaker A. Mousa Mousa, Shaker A., Vandhana Muralidbaran-Chari Muralidbaran-Chari, Vandhana, Paul J. Davis Davis, Paul J. 51

Cancer-associated Thrombosis 51

TF-Vlla-PAR2 Signaling Regulates Angiogenesis 56

TF-Vlla-PAR2 Signaling Regulates Inflammation 58

Role of TF-Vlla in Cellular Signaling 60

Conclusions 60

References 61

5 microRNAs and Angiogenesis / Paul J. Davis Davis, Paul J., Matthew Leinung Leinung, Matthew, Shaker A. Mousa Mousa, Shaker A. 69

Introduction 69

Specific miRNAs and Angiogenesis 73

Endothelial Cells and miRNAs 74

miRNAs and Hypoxia 74

miRNAs and VEGF 75

miRNAs and Hormone-Stimulated Angiogenesis 75

Clinical Targeting of miRNAs 76

References 77

6 Naturally Occurring Angiogenesis Inhibitors / Shaker A. Mousa Mousa, Shaker A., Maii Abu Taleb Taleb, Maii Abu, Paul J. Davis Davis, Paul J. 85

Introduction 85

Nutraceutical-Derived Polyphenol Angiogenesis Inhibitors 86

Marine Nonglycosaminoglycan Sulfated Glycans 89

Natural Lipid Products 89

References 93

7 Integrin Antagonists and Angiogenesis / Shaker A. Mousa Mousa, Shaker A., Noureldien H.E. Darwish Darwish, Noureldien H.E., Paul J. Davis Davis, Paul J. 99

Integrins 99

Integrins and Signaling 100

Cell Surface Membrane Integrins as Potential Drug Discovery Targets 102

Β1 Integrins 103

Β3 Integrins 105

Antagonists of Integrins ανβ3 and ανβ5 Inhibit Angiogenesis 109

Integrin ανβ3 Antagonists Versus Anti-ανβ3 and ανβ3 110

ανβ3 Ligands: Issues in the Development of ανβ3 Antagonists as Therapeutics 110

Diagnostics 111

Integrin-Hormone Crosstalk: Integrin Receptor-Mediated Actions of Thyroid Hormone 112

Conclusions 114

References 115

8 Tyrosine Kinase inhibitors and Angiogenesis / Paul J. Davis Davis, Paul J., Shaker A. Mousa Mousa, Shaker A. 125

Introduction 125

Examples of Specific TKIs 126

Sunitinib 126

Sorafenib 126

Vandetinib 126

Pazopanib 127

Axitinib 127

Nintedanib 127

Impact of Angiogenesis-Active TKIs on Clinical Outcomes 127

Conclusions 128

References 129

9 Tetraiodothyroacetic Acid at Integrin ανβ3: A Model of Pharmaceutical Anti-Angiogenesis / Paul J. Davis Davis, Paul J., Shaker A. Mousa Mousa, Shaker A. 133

Introduction 133

Thyroid Hormone is a Proangiogenic Agent and Tetrac is an Anti-Angiogenic Agent 136

Tetrac, NDAT, and Angiogenesis-Relevant Gene Expression and miaoRNA Expression 137

Tetrac, NDAT, and Actions of Vascular Growth Factors 139

Tetrac and NDAT Actions on Endothelial Cells 139

Anti-Angiogenesis of NDAT in the Retina 140

Anti-Angiogenesis of NDAT in Human Tumor Xenografts 140

Action of NDAT on Mechanisms of Vascular Sprouting 140

Pharmacodynamics of NDAT 141

Side Effect Profile of NDAT 141

Conclusions 142

References 142

10 Anti-Angiogenesis Therapy and its Combination with Chemotherapy: Impact on Primary Tumor and its Metastasis / Shaker A. Mousa Mousa, Shaker A., Thangirala Sudha Sudha, Thangirala, Paul J. Davis Davis, Paul J. 147

Introduction 147

Biomarkers of Angiogenesis 148

Impact of Angiogenesis on Tumor Growth and Metastasis 149

Current Anti-Angiogenic Therapies 150

Bevacizumab in Breast Cancer 150

Monoclonal Antibodies in Other Cancers 151

Tyrosine Kinase Inhibitors 153

Problems Encountered with Anti? Angiogenic Therapy 154

Distinctive Features Of Tumor-Related Angiogenesis 154

Blood Vessel Porosity 154

Interstitial Pressure Increase 155

Angiogenesis and Thrombosis 155

Novel Anti-Angiogenesis Strategies 156

Anti-Angiogenesis and Nanotargeting 157

Conclusions 158

References 158

11 Application of Nanotechnology to Target Tumor Angiogenesis in Cancer Therapeutics / Dhruba J. Bharali Bharali, Dhruba J., Mehdi Rajabi Rajabi, Mehdi, Shaker A. Mousa Mousa, Shaker A. 165

Introduction 165

Angiogenesis 166

Integrins 167

Integrin ανβ3 Targeting with Nanoparticles 167

Integrin ανβ3 Targeting with Tetrac Nanoformulation 168

Gene Therapy Delivery with Nanoparticles 173

Conclusions 174

References 174

12 New Directions in Anti-Angiogenesis Research / Shaker A. Mousa Mousa, Shaker A., Paul J. Davis Davis, Paul J. 179

Introduction 179

Projections 180

Vascular Growth Factors 180

Integrin ανβ3 and Growth Factors 181

Transduction of Growth Factor Signals 182

Hypoxia 183

Inflammation-Related Signaling 183

Conclusions 183

Acknowledgment 184

References 184.

Notes:

Includes index.

Electronic reproduction. Amsterdam Available via World Wide Web.

Description based on online resource; title from digital title page (viewed on February 14, 2017).

ISBN:

9780128026731

0128026731

Publisher Number:

99970596108

Access Restriction:

Restricted for use by site license.